BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
CompanyDrug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
CompanyDrug

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors

Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia
CompanyDrug

Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia

AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
CompanyDrug

AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025

Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs
CompanyDrug

Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs

Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC
CompanyDrug

Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC

Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer
CompanyDrug

Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer

Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes
CompanyDrug

Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes

Sino Biopharmaceutical Announces Breakthrough Phase III Results for Culmerciclib in HR+/HER2‑ Negative Breast Cancer
CompanyDrug

Sino Biopharmaceutical Announces Breakthrough Phase III Results for Culmerciclib in HR+/HER2‑ Negative Breast Cancer

Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC
CompanyDrug

Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC

Anhui Anke Announces HuA21 Success in HER2‑Positive Gastric Cancer
CompanyDrug

Anhui Anke Announces HuA21 Success in HER2‑Positive Gastric Cancer

Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer
CompanyDrug

Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer